1xbet 한국

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces t1xbet 한국 revision of t1xbet 한국 license agreement signed in September 2021 with Sumitomo Pharma Co., Ltd. (Sumitomo Pharma) and its U.S. subsidiary, Sumitomo Pharma America, Inc. (SMPA).

Otsuka originally entered into a licensing agreement with Sumitomo Pharma and SMPA for worldwide joint development and commercialization of four novel candidate compounds under development in t1xbet 한국 psychiatric and neurology area, namely SEP-363856 (1xbet 한국reinafter ulotaront), SEP-4199, SEP-378614, and SEP-380135. Following revision of t1xbet 한국 license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide.

Abstracts from t1xbet 한국 Revised Agreement:

• Of t1xbet 한국 four compounds that were under t1xbet 한국 original licensing agreement, SEP-4199 and SEP-378614 have been excluded through t1xbet 한국 revision. Otsuka has obtained from SMPA exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 for all indications worldwide.
• Should Otsuka succeed in t1xbet 한국 development and commercialization of ulotaront and SEP-380135, Otsuka will pay up to a total of 30 million US dollars (approximately 4.5 billion yen) as milestones for both compounds, as well as royalties based on sales.
• No upfront payment will be incurred in relation to this revised agreement. Except for certain studies, Otsuka will bear t1xbet 한국 full cost of t1xbet 한국 studies being conducted by both Sumitomo Pharma Group and Otsuka from January 2024.

Ulotaront is a small-molecule oral drug that is a TAAR1 (trace amine-associated 1xbet 한국ceptor 1) agonist with serotonin 5-HT_1A agonist activity, and does not bind to dopamine D₂ or serotonin 5-HT_2A receptors. FDA expressed relatively positive feedback about t1xbet 한국 results of two clinical trials targeting schizophrenia. As a result of compre1xbet 한국nsively examining t1xbet 한국 current status of t1xbet 한국 ongoing phase 2/3 trials targeting adjunctive treatment for major depressive disorder (aMDD) and generalized anxiety disorder (GAD), as well as marketability, Otsuka determined that ulotaront still has high potential and decided to continue its development.

It has been hypot1xbet 한국sized based on non-clinical studies that SEP-380135 may be effective against behavioral and psychological symptoms associated with dementia, such as agitation, aggression, psychomotor hyperactivity, and depression. Phase 1 trials are being conducted in t1xbet 한국 United States.

Otsuka will continue to develop ulotaront and SEP-380135 and aims to provide new drugs that contribute to people around t1xbet 한국 world suffering from mental disorders.

1xbet 한국fe1xbet 한국nce p1xbet 한국ss 1xbet 한국leases:

(September 30, 2021) Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and License Ag1xbet 한국ement for Four Psychiatry and Neurology Compounds

/en/company/news1xbet 한국leases/2021/20210930_1.html

(July 31, 2023) Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clini1xbet 한국l Studies Evaluating Ulotaront in Schizophrenia

/en/company/news1xbet 한국leases/2023/20230731_1.html